BioVenture VoiCes with Chris Garabedian Episode 36: Sofinnova Invetments' Jim Healy
14 snips
Mar 9, 2026 Jim Healy, Managing Partner and Chairman at Sofinnova Investments with decades in venture investing focused on therapeutics. He discusses product versus platform tradeoffs, why Sofinnova favors de-risked clinical-stage deals, how board seats and long holds shape outcomes, therapeutic and modality preferences, and how regulatory clarity and pharma interest drive diligence decisions.
AI Snips
Chapters
Transcript
Episode notes
Strategy Shift To Biotech After Return Analysis
- Sofinnova shifted to overweight biotech starting with Fund VII after analyzing returns and seeing stronger performance in therapeutics.
- Fund VII (closed 2007) was ~80% biotech and emphasized capital efficiency and regulatory clarity during the financial crisis.
Prefer De Risked Single Product Bets
- Prefer single-product companies with clear regulatory paths because they're capital efficient and mission-focused despite being binary.
- Target drugs with low clinical technical risk and high execution risk to improve odds of exits or acquisitions.
Platform Upside Versus Product Capital Tradeoff
- Platforms can scale value across multiple programs if funded, but require higher capital and burn; single-product successes like InterMune and Corvidia delivered huge exits.
- The tradeoff is capital intensity versus potential multi-program upside and market attribution to the platform.